In today’s fast-paced world, the quest for longevity and overall health is more relevant than ever.
Recently, the market for longevity supplements has exploded, offering a wide range of options from peptide injections and NAD boosters to various pills and powders, all claiming anti-aging benefits. This plethora of products makes it increasingly challenging to distinguish genuine scientific advancements from clever marketing strategies.
Amidst this crowded market, NOVOS stands out by emphasizing a scientific approach. This biotechnology company offers the Core Clinical formula, which aims to address all 12 key hallmarks of aging. This innovative formula combines naturally occurring compounds such as Ca-AKG, glucosamine sulfate, magnesium malate, L-theanine, and hyaluronic acid. Collectively, these ingredients support various aspects of health, including mitochondrial energy, ATP production, sleep quality, and recovery.
In a preclinical study, mice administered NOVOS Core Clinical exhibited an 18% increase in lifespan on average. Although results from animal studies don’t always predict human outcomes, the initial findings warranted further investigation. Recently, NOVOS Core Clinical has been evaluated in a randomized, placebo-controlled human clinical trial conducted at the University of Surrey.
The study focused on 61 participants over the age of 40 who did not have diagnosed cardiovascular issues. For six months, their experiences with either the Novos supplement or a placebo were compared. Findings indicated notable improvements in several validated markers of vascular aging for those taking NOVOS.
According to NOVOS, the Core Clinical formula led to a more than 3.4% enhancement in endothelial function.
Participants using NOVOS demonstrated significantly improved arterial flexibility, with a difference of −1.18 m/s when compared to the placebo group after the six-month period. This enhancement is particularly noteworthy given the common trend of increasing arterial stiffness with age.
Moreover, the supplement group exhibited a reduction in systolic blood pressure, defying the normal trend of gradual increases linked with aging. The average reduction was −6.1 mmHg between the NOVOS and placebo groups.
Additionally, researchers observed a boost of nearly 3% in endothelial function, an important indicator of blood vessel health. Such levels of improvement are typically associated with regular, vigorous exercise; however, in this case, the only differing variable was the intake of NOVOS.
“These findings indicate that addressing multiple biological pathways related to vascular aging could be a promising strategy for enhancing vascular health earlier in life, potentially preventing disease,” commented Professor Christian Heiss, MD, Senior Author and Professor of Cardiovascular Medicine at the University of Surrey.
Professor Heiss further noted that these benefits occurred without any changes in lipid levels, implying that it may be possible to enhance blood vessel function as a distinct and modifiable aspect of aging.
“The magnitude and consistency of these impacts across various vascular endpoints are uncommon for a nutritional intervention within a healthy cohort,” he added.
These results stem from a randomized, double-blind, placebo-controlled human study, where individual outcomes may differ. It’s crucial to consult with a healthcare provider before starting any supplement regimen.
This article is authored by Miska Salemann, a reporter for the New York Post. As a health-conscious member of Gen Z, Miska engages experts to explore the advantages, safety, and design of both cutting-edge and established fitness equipment, workout wear, dietary supplements, and more. Miska tests wellness products, from Bryan Johnson’s Blueprint Longevity Mix to the popular Oura Ring and Jennifer Aniston’s favorite workout platform — often accompanied by her adorable toddler. Prior to joining The Post, Miska covered lifestyle and consumer subjects for the U.S. Sun and The Cannon Beach Gazette.
